We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
A phase 2 study of methotrexate, etoposide, dexamethasone, and pegaspargase chemotherapy for newly diagnosed, relapsed, or refractory extranodal natural killer/T-cell lymphoma, nasal type: a multicenter trial in Northwest China.
- Authors
Liang, Rong; Gao, Guang‐xun; Chen, Jie‐ping; Wang, Ji‐shi; Wang, Xiao‐min; Zeng, Yun; Bai, Qing‐xian; Zhang, Tao; Yang, Lan; Dong, Bao‐xia; Gu, Hong‐tao; Shu, Mi‐mi; Hao, Cai‐xia; Wang, Jian‐hong; Zhang, Na; Chen, Xie‐qun; Gao, Guang-Xun; Chen, Jie-Ping; Wang, Ji-Shi; Wang, Xiao-Min
- Abstract
The nasal type of extranodal natural killer/T-cell lymphoma is a rare aggressive lymphoma with poor prognosis. To discover a successful treatment, we investigated the efficacy and safety of chemotherapy with methotrexate, etoposide, dexamethasone, and polyethylene glycol-asparaginase (MESA). Three cycles of MESA were administered to 46 patients with new or relapsed/refractory natural killer/T-cell lymphoma. Complete response after 3 treatment cycles was 43.5%, the overall response rate was 87%, and 2-year overall survival was 83.4%. Complete response was significantly better for newly diagnosed patients than for patients with relapsed/refractory disease. Patients with newly diagnosed disease had a significantly better overall response rate after 1, but not after 2 or 3 treatment cycles. Overall survival and progression-free survival did not differ over 2 years. Grade 1/2 toxicities were frequent, but MESA was associated with fewer grade 3/4 events or treatment-related deaths. These results will require confirmation in larger prospective trials.
- Publication
Hematological Oncology, 2017, Vol 35, Issue 4, p619
- ISSN
0278-0232
- Publication type
journal article
- DOI
10.1002/hon.2325